ArticleAnnals of gastroenterological surgery2021
Prognostic impact of thoracic duct lymph node metastasis in esophageal squamous cell carcinoma.
Article in Annals of gastroenterological surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.Annals of surgical oncology · 2025Trial
- The White Plane in Esophageal Surgery: A Novel Anatomical Landmark with Prognostic Significance.Cancers · 2025Article
- Prognosis of Robot-Assisted Esophagectomy with Thoracic Duct Resection in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2025Article
- Development in Esophagectomy for Esophageal Cancer: The Current Standing Point of Robotic Surgery.Cancers · 2025Review
- Robotic esophagectomy with function-preserving radical mediastinal lymphadenectomy for esophageal cancer.Annals of gastroenterological surgery · 2025Review
- ASO Author Reflections: Should we Change the Indication for Thoracic Duct Resection Based on the Response to Neoadjuvant Chemotherapy?Annals of surgical oncology · 2025Article
- Hidden in plain sight: unknown anatomy depiction and applications of the aorto-esophageal ligament.Mediastinum (Hong Kong, China) · 2025Review
- Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.BMC cancer · 2024Article
- Oncological and physiological impact of thoracic duct resection in esophageal cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Article
- Is Thoracic Duct Resection Necessary for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy? A Propensity-Matched Analysis Based on the Comprehensive Registry of Esophageal Cancer in Japan.Annals of surgical oncology · 2023Article
- Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Article
- Prognostic impact of thoracic duct lymph node metastasis in esophageal squamous cell carcinoma.Annals of gastroenterological surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe have previously reported the existence of lymph nodes surrounding the thoracic duct ( TDLN) and transthoracic esophagectomy (TTE) with thoracic duct (TD) resection increased the number of lymph nodes (LNs) retrieved. The current study aims to evaluate the prognostic impact of TDLN metastasis in esophageal cancer patients subdivided by its location and comparing the patients' survival with those with extra-regional LN metastasis.
methodsPatients who underwent TTE with TD resection for esophageal squamous cell carcinoma (ESCC) were reviewed. Patients were classified into those with or without TDLN metastasis, and clinicopathological factors were compared between groups. TDLN was further divided into TDLN-Ut/Mt/Lt based on the location in the mediastinum. The relapse-free survival (RFS) and overall survival (OS) were compared between groups.
resultsOf 232 patients, TDLN metastasis was observed in 17 (7%). RFS and OS were significantly worse in the TDLN metastasis group. TDLN metastasis was shown to be an independent prognostic factor for RFS and OS in the multivariate analysis. The negative prognostic impact of TDLN metastasis was evident in TDLN-Mt/Lt. The RFS and OS of patients with TDLN metastasis were almost identical to those with positive LN metastasis in extra-regional LNs.
conclusionTDLN metastasis was proven to be a strong prognostic indicator. Although the TDLN has been included in the classification of regional LN in the current staging systems, it could be independently classified from the current regional LNs. Given that neoadjuvant therapy has been a standard, we might need to introduce adjuvant therapy when TDLN metastasis is observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.